Skip to content

Amylyx Pharmaceuticals, Inc. AMLX Other Working Capital

Other Working Capital at other companies

Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
-$178K
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
-$27K-640%
AdaptHealth logo
AdaptHealthAHCO
-$786K
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$1.29M+394%
uniQure logo
uniQureQURE
$242K-93.9%
Biohaven logo
BiohavenBHVN
$837K-70.6%

Other financials

Income statement

See full
Revenue-
Gross profit-
Operating income-$43.8M-15.8%
Net income-$41.3M-15.0%
EPS (diluted)-$0.37+11.9%

Balance sheet

See full
Cash & equivalents$229.1M+283%
Total debt$5.6M+307%
Total equity$273.2M+35.6%
Total assets$293.6M+33.7%

Cash flow

See full
Operating cash flow-$36.9M+7.4%
CapEx$86.0K+330%
Free cash flow-$28.0M+52.6%

Valuation

See full
Market cap$1.89B+390%

Profitability

See full
Gross margin100%+6.9pp
Operating margin-47,349.8%-47,409pp
Net margin-45,096.2%-45,152pp
FCF margin-39,826.7%-39,847pp

Returns & leverage

See full
Return on equity-63.3%-12.2pp
Debt / equity0.0×
Current ratio17.9×+5.8×

Where this comes from

Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.

The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amylyx Pharmaceuticals, Inc.'s other working capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amylyx Pharmaceuticals, Inc.'s other working capital?
Amylyx Pharmaceuticals, Inc. (AMLX) reported other working capital of -$53K in Q1 2026.
What does other working capital mean?
Net change in working capital items not separately classified — a residual balancing item.